POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine aims to shield transplant patients from Cancer-Causing virus
⭐️ VACCINE ⭐️ TerminatedThis early-stage trial tests a vaccine (OSU-2131) designed to help the immune system fight Epstein-Barr virus (EBV), which can cause cancer in people with weakened immune systems. The study includes healthy volunteers and patients waiting for a solid organ transplant, who are at …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 30, 2026 15:51 UTC
-
New strategy aims to tame common virus threat after stem cell transplants
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or related disorders. About 153 participants will be monitored to see if delaying or adjusting anti-CMV therapy can s…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Engineered immune cells target tough lymphoma after transplant
Disease control OngoingThis early-phase study tests a new immune cell therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially engineered T-cells designed to find and attack cancer cells. The main goal is to check safety and find the …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a personalized cell therapy for adults with certain B-cell blood cancers that have returned after prior treatment. Doctors take a patient's own white blood cells, modify them in a lab to better recognize and attack cancer cells, and infuse them back a…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC